002118SZSE

Jilin Zixin Pharmaceutical Co., Ltd. 2022 Annual Report (Corrected Version)

*ST Zixin Co., Ltd.··235 pages

✨ AI Summary

The purpose of this announcement is to present the corrected annual report for Jilin Zixin Pharmaceutical Co., Ltd. for 2022. Key figures include a revenue of approximately 143.51 million yuan, a net loss attributable to shareholders of about 1.19 billion yuan, and a significant decline in revenue compared to the previous year. The report highlights the company's challenges in the pharmaceutical industry and its strategic focus on traditional Chinese medicine and ginseng products.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Important Notes, Directory, and Definitions

The Board of Directors, Supervisory Board, and senior management of Jilin Zixin Pharmaceutical Co., Ltd. guarantee that the content of the annual report is true, accurate, and complete, with no false records, misleading statements, or significant omissions, and they bear individual and joint legal responsibilities. The responsible person, Meng Xiangjin, the head of accounting, Luan Fumei, and the head of the accounting institution (accounting supervisor), Li Changting, declare: they ensure the truthfulness, accuracy, and completeness of the financial report in this annual report. All directors have attended the board meeting to review this report. The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves.

Directory

  1. Important Notes, Directory, and Definitions ........................................................................................................... 2
  2. Company Profile and Key Financial Indicators ........................................................................................................ 7
  3. Management Discussion and Analysis .................................................................................................................... 11
  4. Corporate Governance .............................................................................................................................................. 41
  5. Environmental and Social Responsibility .............................................................................................................. 57
  6. Important Matters .................................................................................................................................................... 59
  7. Changes in Shares and Shareholder Information .................................................................................................. 76
  8. Preferred Shares Information .................................................................................................................................. 85
  9. Bond Information .................................................................................................................................................... 86
  10. Financial Report ..................................................................................................................................................... 87

Documents for Inspection

  1. Financial statements signed and sealed by the responsible person, head of accounting, and head of the accounting institution (accounting supervisor).
  2. Original copies of all company documents publicly disclosed in newspapers designated by the China Securities Regulatory Commission during the reporting period.
  3. Location of the above inspection documents: Office of the Secretary of the Board of Directors.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.